Canada markets closed

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0200+0.0200 (+2.00%)
At close: 04:00PM EST
1.0003 -0.02 (-1.93%)
After hours: 04:06PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.0000
Open0.9904
Bid0.9928 x 3200
Ask1.0000 x 1800
Day's Range0.9901 - 1.0400
52 Week Range0.5900 - 1.3900
Volume506,369
Avg. Volume437,861
Market Cap127.81M
Beta (5Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-0.2400
Earnings DateMar 20, 2024 - Mar 25, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.58
  • Simply Wall St.

    We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • GlobeNewswire

    Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

    SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announced that the first patient has been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (R

  • GlobeNewswire

    Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

    SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that the (Z)-endoxifen arm of the ongoing Phase 2 I-SPY 2 clinical trial has fully enrolled. In the study, (Z)-endoxifen, Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), is being evaluated as a neoadjuvant treatment for